ALK and non-small cell lung carcinoma: Approximately a third (32%) of patients with RET+ NSCLC were found to have baseline brain metastases at initial diagnosis, which is comparable to the incidence detected in ALK+ NSCLC and higher than that in ROS1+ NSCLC (Table 3).